<DOC>
	<DOCNO>NCT01064492</DOCNO>
	<brief_summary>PF 04620110 acylCoA : diacylglycerol acyltransferase 1 ( DGAT1 ) inhibitor develop treatment type 2 diabetes mellitus ( T2DM ) . It anticipate PF 04620110 anti diabetic effect inhibition intestinal triglyceride absorption potentially weight loss . The primary purpose study evaluate pharmacokinetics , safety tolerability multiple oral formulation PF 04620110 administer healthy volunteer .</brief_summary>
	<brief_title>A Phase 1 Study To Estimate The Relative Bioavailability And Food Effect Of PF-04620110 In Healthy Adult Subjects</brief_title>
	<detailed_description />
	<criteria>Healthy male and/or female subject age 18 55 year , inclusive ( Healthy define clinically relevant abnormality identify detailed medical history , full physical examination , include blood pressure pulse rate measurement , 12 lead ECG clinical laboratory test ) . Women must non childbearing potential . Body Mass Index ( BMI ) 17.5 35.5 kg/m2 ; total body weight &gt; 50 kg ( 110 lb ) . Evidence history clinically significant hematological , renal , endocrine , pulmonary , gastrointestinal , cardiovascular , hepatic , psychiatric , neurologic , allergic ( include drug allergy , exclude untreated , asymptomatic , seasonal allergy time dose ) disease clinical finding Screening . Any condition possibly affect drug absorption ( eg , gastrectomy ) . A positive urine drug screen .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>March 2010</verification_date>
</DOC>